Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy

NCT04923594 is registered in ClinicalTrials.gov with NLS Pharmaceutics as lead sponsor.

NCT NCT04923594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04923594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy
Lead sponsor
NLS Pharmaceutics
Phase
Phase 2
Overall status
Completed
Start date
September 13, 2021
Completion date
June 30, 2022
Enrollment
67 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

cataplexy narcolepsy, excessive daytime sleepiness, narcolepsy